EBV: Immunobiology and host response

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 904-914

  Moss, Denis J ^a   Burrows, Scott R ^a   Khanna, Rajiv ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929271173     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.052     Document Type: Chapter

References (68)

1. Annels, N. E., Callan, M. F., Tan, L., and Rickinson, A. B. (2000). Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J. Immunol., 165, 4831-4841.
2. Bejarano, M. T. and Massuci, M. G. (1998). Interleukin-10 abro-gates the inhibition of Epstein-Barr virus-induced B-cell trans-formation by memory T-cell responses. Blood, 92, 4256-4262.
3. Bharadwaj, M., Parsons, P. G., and Moss, D. J. (2001). Cost-efficient quantification of enzyme-linked immunospot. Biotechniques, 30, 36-38.
4. Bishop, C. J., Moss, D. J., Ryan, J. M., and Burrows, S. R. (1985). T lymphocytes in infectious mononucleosis. II. Response in vitro to interleukin-2 and establishment of T-cell lines. Clin. Exp. Immunol., 60, 70-77.
5. Brion, A., Cahn, J. Y., Mougin, C. et al. (1995). Herpes virus-related lymphoproliferative disorders following allogeneic bone mar-row transplantation: Clinical and biological characteristics of six cases. Nouv. Rev. Fr. Hematol., 37, 289-296.
6. Brooks, J. M., Murray, R. J., Thomas, W. A., Kurilla, M. G., and Rickin-son, A. B. (1993). Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. Exp. Med., 178, 879-887.
7. Burrows, S. R., Khanna, R., Burrows, J. M., and Moss, D. J. (1994). An alloresponse in humans is dominated by cytotoxic T lym-phocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: Implications for graft-versus-host disease. J. Exp. Med., 179, 1155-1161.
8. Burrows, S. R., Silins, S. L., Moss, D. J., Khanna, R., Misko, I. S., and Argaet, V. P. (1995). T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med., 182, 1703-1715.
9. Burrows, S. R., Elkington, R. A., Miles, J. J. et al. (2003). Promis-cuous CTL recognition of viral epitopes on multiple human leukocyte antigens: Biological validation of the proposed HLA A24 supertype. J. Immunol., 171, 1407-1412.
10. Callan, M. F. (2003). The evolution of antigen-specific CD8+ Tcell responses after natural primary infection of humans with Epstein-Barr virus. Viral Immunol., 16, 3-16.
11. Callan, M. F., Steven, N., Krausa, P. et al. (1996). Large clonal expan-sions of CD8+ T cells in acute infectious mononucleosis. Nat. Med., 2, 906-911.
12. Callan, M. F., Tan, L., Annels, N. et al. (1998). Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J. Exp. Med. 187, 1395-1402.
13. Callan, M. F., Fazou, C., Yang, H. et al. (2000). CD8(+) T-cell selec-tion, function, and death in the primary immuneresponse in vivo. J. Clin. Invest., 106, 1251-1261.
14. Cohen, J. I. (1999) The biology of Epstein-Barr virus:lessons learned from the virus and the host. Curr. Opin. Immunol., 11, 365-370.
15. Cohen, J. I. and Lekstrom, K. (1999). Epstein-Barr virus BARF1 pro-tein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J. Virol., 73, 7627-7632.
16. Couedel, C., Bodinier, M., Peyrat, M. A., Bonneville, M., Davodeau, F., and Lang, F. (1999). Selection and long-term persistence of reactive CTL clones during an EBV chronic response are deter-mined by avidity, CD8 variable contribution compensating for differences in TCR affinities. J. Immunol., 162, 6351-6358.
17. Dukers, D. F., Meij, P., and Vervoort, M. B. (2000). Direct immuno-suppressive effects of EBV-encoded latent membrane protein 1. J. Immunol., 165, 663-670.
18. Gregory, C. D., Kirchgens, C., Edwards, C. F. et al. (1987). Epstein-Barr virus-transformed human precursor B cell lines: Altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. Eur. J. Immunol., 17, 1199-1207.
19. Hislop, A. D., Gudgeon, N. H., Callan, M. F. et al. (2001). EBV-specific CD8+ T cell memory: Relationships between epitope specificity, cell phenotype, and immediate effector function. J. Immunol., 167, 2019-2029.
20. Hislop, A. D., Annels, N. E., Gudgeon, N. H., Leese, A. M., and Rickin-son, A. B. (2002). Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med., 195, 893-905.
21. Jones, R. J., Smith, L. J., Dawson, C. W., Haigh, T., Blake, N. W., and Young, L. S. (2003). Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. Virology, 313, 663-676.
22. Khanna, R. (1998). Tumour surveillance: Missing peptides and MHC molecules. Immunol. Cell Biol., 76, 20-26.
23. Khanna, R. and Burrows, S. R. (2000). Role of cytotoxic t lym-phocytes in epstein-barr virus-associated diseases. Annu. Rev. Microbiol., 54, 19-48.
24. Khanna, R., Burrows, S. R., Argaet, V., and Moss, D. J. (1994). Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol., 6, 639-645.
25. Khanna, R., Rowe, M., Jacob, C. A. et al. (1995). Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol., 25, 1374-1384.
26. Khanna, R., Burrows, S. R., Moss, D. J., and Silins, S. L.(1996). Peptide transporter (TAP1 and TAP-2)-independent endogenous pro-cessing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J. Virol., 70, 5357-5362.
27. Khanna, R., Burrows, S. R., Thomson, S. A. et al. (1997). Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J. Immunol., 158, 3619-3625.
28. Khanna, R., Busson, P., Burrows, S.R. et al. (1998). Molecular char-acterization of antigen-processing function in nasopharyn-geal carcinoma (NPC): Evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Can-cer Res., 58, 310-314.
29. Kjer-Nielsen, L., Clements, C. S., Purcell, A. W. et al. (2003). A struc-tural basis for the selection of dominant alphabeta T cell recep-tors in antiviral immunity. Immunity, 18, 53-64.
30. Lautscham, G., Haigh, T., Mayrhofer, S. et al. (2003). Identification ofa TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. J. Virol., 77, 2757-2761.
31. Lee, S. P., Thomas, W. A., Blake, N. W., and Rickinson, A. B. (1996). Transporter (TAP)-independent processing of a multi-ple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur. J. Immunol., 26, 1875-1883.
32. Lee, S. P., Constandinou, C. M., Thomas, W. A. et al. (1998). Anti-gen presenting phenotype of hodgkin reed-sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cyto-toxic T-cell recognition [In Process Citation]. Blood, 92, 1020-1030.
33. Leen, A., Meij, P., Redchenko, I. et al. (2001). Differential immuno-genicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol., 75, 8649-8659.
34. Levitskaya, J., Coram, M., Levitsky, V. et al. (1995). Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 375, 685-688.
35. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., and Masucci, M. G. (1997). Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl Acad. Sci. USA, 94, 12616-12621.
36. Li, Q., Spriggs, M. K., Kovats, S. et al. (1997). Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol., 71, 4657-4662.
37. Marshall, N. A., Vickers, M. A., and Barker, R. N. (2003). Regulatory T cells secreting IL10 dominate the immune response to EBV latent membrane protein 1. J. Immunol., 170, 6183-6189.
38. Miles, J. J., Elhassen, D., Borg, N. A., et al. (2005). CTL recogni-tion of a bulged viral peptide involves biased TCR selection. J. Immunol., 175, 3826-3834.
39. Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., and Mosmann, T. R. (1990). Homology of cytokine synthesis inhibitory factor (IL-10) to theEpstein-Barr virus gene BCRF1. Science, 248, 1230-1234.
40. Moss, D. J., Burrows, S. R., Castelino, D. J., Kane, R. G., Pope, J. H., and Rickinson, A. B. (1983). A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and nonendemic regions of Papua New Guinea. Int. J. Cancer, 31, 727-732.
41. Moss, D. J., Bishop, C. J., Burrows, S. R., and Ryan, J. M. (1985). T lymphocytes in infectious mononucleosis. I. T-cell death in vitro. Clin. Exp. Immunol., 60, 61-69.
42. Muller, A., Schmitt, L., Raftery, M., and Schonrich, G. (1998). Paral-ysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction. Eur. J. Immunol., 28, 3488-3498.
43. Munz, C., Bickham, K. L., and Subklewe, M. (2000). Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med., 191, 1649-1660.
44. Pai, S. and Khanna, R. (2002). Role of LMP1 in immune control of EBV infection. Semin. Cancer Biol., 11, 455-460.
45. Paludan, C., Bickham, K., Nikiforow, S. et al. (2002). Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lym-phoma cells. J. Immunol., 169, 1593-1603.
46. Precopio, M. L., Sullivan, J. L., Willard, C., Somasundaran, M., and Luzuriaga, K. (2003). Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infec-tion. J. Immunol., 170, 2590-2598.
47. Reedman, B. M., Hilgers, J., Hilgers, F., and Klein, G. (1975). Immunofiuorescence and anti-complement immunofiuores-cence absorption tests for quantitation of Epstein-Barr virus-associated antigens. Int. J. Cancer, 15, 566-571.
48. Ressing, M. E., Keating, S. E., van Leeuwen, D. et al. (2005). Impaired transporter associated with antigen processing-dependent protein transport during productive EBV infection. J. Immunol., 174, 6829-6838.
49. Rickinson, A. B. and Kieff, E. (1996). Epstein-Barr virus. In Fields Virology. B. N. Fields, D. M. Knipe, and P. M. Howley, eds., pp. 2397-2446. Philadelphia: Lippincott-Raven Publishers.
50. Rooney, C. M., Smith, C. A., Ng, C. et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet, 345, 9-13.
51. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 401, 708-712.
52. Schmidt, C. W. and Misko, I. S. (1995). The ecology and pathology of Epstein-Barr virus. Immunol. Cell Biol., 73, 489-504.
53. Sherritt, M. A., Bharadwaj, M., Burrows, J. M. et al. (2003). Recon-stitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttrans-plant lymphoma after adoptive immunotherapy. Transplan-tation, 75, 1556-1560.
54. Silins, S. L., Cross, S. M., Elliott, S. L. et al. (1996). Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J. Exp. Med., 184, 1815-1824.
55. Silins, S. L., Cross, S. M., Elliott, S. L. et al. (1997). Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Int. Immunol., 9, 1745-1755.
56. Silins, S. L., Cross, S. M., Krauer, K. G., Moss, D. J., Schmidt, C. W., and Misko, I. S. (1998). A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. J. Clin. Invest., 102, 1551-1558.
57. Silins, S. L., Sherritt, M. A., Silleri, J. M. et al. (2001). Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood, 98, 3739-3744.
58. Slivnick, D. J., Ellis, T. M., Nawrocki, J. F., and Fisher, R. I. (1990). The impact of Hodgkin's disease on the immune system. Semin. Oncol, 17, 673-682.
59. Spear, P. G. and Longnecker, R. (2003). Herpesvirus entry: An update. J. Virol., 77, 10179-10185.
60. Spriggs, M. K., Armitage, R. J., Comeau, M. R. et al. (1996). The extra-cellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J. Virol., 70, 5557-5563.
61. Steven, N. M., Leese, A. M., Annels, N. E., Lee, S. P., and Rickinson, A. B. (1996). Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med.184, 1801-1813.
62. Strockbine, L. D., Cohen, J. I., Farrah, T. et al. (1998). The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J. Virol., 72, 4015-4021.
63. Takaoka, A., Hayakawa, S., Yanai, H. et al. (2003). Integra-tion of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature, 424, 516-523.
64. Tellam, J., Connolloy, G., Green, K. J. et al. (2004). Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus encoded nuclear antigen 1: Functional evidence for DriPs as a source of endogenously processed epitopes. J. Exp. Med., 199, 1421-1431.
65. Topalian, S. L., Rivoltini, L., Mancini, M., Ng, J., Hartzman, R. J., and Rosenberg, S. A. (1994). Melanoma-specific CD4+ T lym-phocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer, 58, 69-79
66. Uchida, J., Yasui, T., Takaoka-Shichijo, Y. et al. (1999). Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science, 286, 300-303.
67. Voo, K. S., Fu, T. Wang, H. Y. et al. (2004). Evidence for the presen-tation of major histocompatibility complex class Irestricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lym-phocytes. J. Exp. Med., 199, 459-470.
68. Yin, Y., Manoury, B., and Fahraeus, R. (2003). Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science, 301, 1371-1374.